Welcome to our dedicated page for EXELIXIS SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
Exelixis, Inc. filed a current report to disclose that on January 11, 2026 it issued a press release with preliminary, unaudited financial results for the fiscal year ended January 2, 2026. The release also provided financial guidance for the fiscal year ending January 1, 2027 and included an update on the company’s business.
The company notes that the audit of its fiscal 2025 financial statements is ongoing and could lead to changes in the information contained in the press release. Exelixis states it plans to report its audited financial results for the fiscal year ended January 2, 2026 on February 10, 2026. The press release is furnished as Exhibit 99.1 and is not deemed filed for liability purposes.
Exelixis, Inc. (EXEL) director David Johnson, together with Caligan Partners LP, reported an open-market purchase of 27,532 shares of common stock on 11/25/2025 at a price of $43.122 per share. After this transaction, 1,553,262 shares are reported as indirectly owned through Caligan-managed funds and accounts, while 18,176 shares are reported separately, which include 9,088 shares that will be issued upon vesting of restricted stock units to Johnson. The reporting persons state they disclaim beneficial ownership of the securities beyond any pecuniary interest and note that Caligan may be deemed a director by deputization because Johnson serves on the Exelixis board.
Exelixis, Inc. executive reports insider stock sales. The company’s EVP, Commercial, filed a Form 4 showing sales of a total of 72,230 shares of Exelixis common stock on November 20–21, 2025.
On November 20, 2025, the executive sold 10,000 shares at a weighted average price of $42.11, while a spouse’s account sold 23,539 shares at a weighted average price of $41.93, and a 401(k) account sold 10,648 shares at a weighted average price of $41.77. On November 21, 2025, the executive sold 28,043 shares at a weighted average price of $42.58.
Following these transactions, the executive beneficially owns 374,029 shares, consisting of Exelixis common stock that will be issued upon vesting of restricted stock units and performance-based restricted stock units, each representing the right to receive one share of common stock.
Exelixis, Inc. (EXEL) reported an insider stock gift by a senior executive. The company’s EVP of Research and Development filed a Form 4 disclosing that on November 21, 2025, they gifted 24,000 shares of Exelixis common stock to a donor-advised fund at a reported price of $0, reflecting a charitable transfer rather than a market sale.
After this gift, the executive beneficially owned 640,778 shares directly, which includes 431,306 shares of common stock scheduled to be issued upon vesting of restricted stock units and performance-based restricted stock units. The filing also shows 5,835 shares held indirectly through the Exelixis, Inc. 401(k) Plan based on a plan statement dated November 20, 2025.
Exelixis, Inc. officer reports beneficial ownership of company stock. The SVP and General Counsel is shown as beneficially owning 90,441 shares of Exelixis common stock directly, including 80,575 shares that will be issued upon vesting of restricted stock units and performance-based restricted stock units, and 556 shares acquired under the company’s 2000 Employee Stock Purchase Plan. In addition, 5,527 shares are held indirectly through the Exelixis 401(k) Plan as of November 7, 2025.
Exelixis, Inc. (EXEL) director reports stock gift. A company director reported gifting 1,044 shares of Exelixis common stock on 11/17/2025 to a not-for-profit organization. The transaction was coded as a gift with a reported price of $0, reflecting that it was not a sale. After this transfer, the reporting person beneficially owns 42,282 shares of Exelixis common stock, including 18,900 shares that will be issued upon vesting of restricted stock units, where each RSU represents one share of common stock.
Exelixis, Inc. director filed a Form 4 reporting the sale of 100,000 shares of common stock on 11/12/2025 at a $43.55 weighted average price, with sales executed between $43.55 and $43.58.
After the transaction, the reporting person beneficially owned 1,189,228 shares directly. This amount includes 9,812 RSUs, each representing the right to receive one share upon vesting.
Exelixis (EXEL) President and CEO Michael M. Morrissey filed a Form 4 reporting charitable and estate-planning stock transfers. On 11/11/2025, he gifted 160,000 shares of common stock to the Bombora Rise Foundation. On 11/12/2025, he gifted 101,548 shares to the Morrissey Family Living Trust and 80,000 shares to a donor advised fund. All gifts were at a reported price of $0 per share (transaction code G).
Following these transactions, the filing shows 1,714,404 shares held by the Morrissey Family Living Trust and 17,728 shares held via the Exelixis 401(k) Plan. It also notes 1,416,692 shares that will be issued upon vesting of RSUs and PSUs, each representing one share of common stock.
Exelixis, Inc. executive reports stock sale and updated holdings. The EVP of Research and Development sold 48,383 shares of Exelixis common stock on 11/11/2025 at a weighted average price of $42.50 per share, in multiple trades between $42.50 and $42.58. After this transaction, the executive beneficially owns 664,778 shares, including 431,306 shares that will be issued upon vesting of restricted stock units and 5,835 shares held through the Exelixis 401(k) Plan as of November 10, 2025. The filing is made by a single reporting person in the capacity of officer.
Exelixis (EXEL) director reported insider activity on 11/11/2025. The reporting person exercised 5,784 options at $23.24 per share, then sold 5,784 shares at $42.03 and 18,838 shares at a $41.9 weighted average (sales ranged from $41.81 to $42.02).
Following these transactions, the filing shows 21,380 shares beneficially owned, which footnote (1) states includes shares to be issued upon vesting of RSUs. The option exercised was part of a grant that became fully exercisable on January 5, 2024 and expires January 4, 2031. After the reported transactions, 16,710 derivative securities (options) remain beneficially owned.